DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software
DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
- DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
- The software allows users to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
- AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for their drug discovery efforts.
- After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.